EX-10.15



 Exhibit 10.15 

FINAL 
 AMENDED AND RESTATED
EXCHANGE AGREEMENT 
 THIS AMENDED AND RESTATED EXCHANGE AGREEMENT (this “Agreement”) is entered into as of October 24,
2014 among: 
  

	(1)	VX PARTNERS INC., an Ontario corporation (“VX1 GP”); 

  

	(2)	VX2 GENERAL PARTNER INC., an Ontario corporation (“VX2 GP”) 

  

	(3)	VACCINEX PRODUCTS, LP, a Delaware limited partnership (“LP”); 

  

	(4)	VACCINEX, INC., a Delaware corporation (“Vaccinex”); 

  

	(5)	FCMI FINANCIAL CORPORATION, an Ontario corporation (“FCMI”); 

  

	(6)	FCMI PARENT CO., a Nova Scotia Unlimited Liability Company (“FCMI Parent”). 


Each of the above are referred to herein individually, as a “Party,” and collectively, as the “Parties.” 

WHEREAS certain of the Parties, together with VX Limited Partnership, an Ontario limited partnership (“VX LP”), VX Therapeutics
Limited Partnership, a Delaware limited partnership (“VX1”), Vaccinex Products, LLC, a Delaware limited liability company (“Vaccinex Sub”), and FEZ Financial Corporation, an Ontario corporation, entered into a
certain Exchange Agreement, dated as of June 18, 2012 (the “Prior Agreement”); 
 AND WHEREAS Vaccinex Sub merged with
and into Vaccinex with Vaccinex surviving such merger and Vaccinex succeeded to the rights of Vaccinex Sub under the Prior Agreement; 
 AND
WHEREAS VX LP was liquidated and dissolved and the units of limited partnership interest in VX1 held by VX LP were distributed to VX LP’s limited partners; 

AND WHEREAS VX2 Limited Partnership (“VX2 LP”) was liquidated and dissolved and the units of limited partnership interest in VX2
(Delaware) Limited Partnership (“VX2”) held by VX2 LP were distributed to VX2 LP’s limited partners; 
 AND WHEREAS
immediately prior to the execution and delivery of this Agreement, VX1 and VX2 consolidated, with LP resulting from such consolidation (the “Consolidation”); 

AND WHEREAS pursuant to the Consolidation, LP issued units of limited partnership interest (the “Units”) to the limited partners of
VX1 and VX2 (each such limited partner, other than Vaccinex, shall be an “Investor” hereunder for so long as such person holds Units); 

AND WHEREAS VX1 GP was the general partner of VX1 prior to the Consolidation, and VX2 GP was the general partner of VX2 prior to the Consolidation;

 AND WHEREAS following the Consolidation, Vaccinex is the general partner of LP and one of the limited partners of LP; 







 AND WHEREAS pursuant to the Prior Agreement, Vaccinex and the limited partners of VX LP had certain
exchange rights to cause the exchange of 3.4 units of limited partnership interest of VX LP for 1 Vaccinex Share (as defined below); 
 AND
WHEREAS prior to the Consolidation, VX1 and VX2 effected a reverse unit split such that following the Consolidation, the number of Units held by the Investors in the aggregate is equal to the number of Vaccinex Shares issuable in the aggregate
under this Agreement; 
 AND WHEREAS that certain Agreement and Omnibus Amendment dated as of June 18, 2012 (“Omnibus
Amendment”), entered into by certain of the Parties, was terminated pursuant to the Consolidation; 
 AND WHEREAS VX1 GP and VX2 GP
are entering into this agreement as agent on behalf of the Investors and, in connection with approving the Consolidation, the Investors approved this Agreement; 

AND WHEREAS pursuant to Section 18 of the Prior Agreement, the Prior Agreement may be amended by the written agreement of Vaccinex and VX GP;

 AND WHEREAS in connection with the Consolidation and the termination of the Omnibus Amendment, all of the Parties agree to amend and restate
the Prior Agreement to provide the Investors and Vaccinex the right to exchange, or cause the exchange, of Units for Vaccinex Shares on the terms and subject to the conditions herein. 

NOW THEREFORE THIS AGREEMENT WITNESSETH that in consideration of the mutual covenants and agreements herein contained and other good and valuable
consideration, the Parties hereby agree to amend and restate the Prior Agreement in its entirety as follows: 
  

	1.	As used herein, the following terms have the following meanings: 

  

	    	“Exchange” means the transfer by an Investor to Vaccinex of the number of Units in exchange for a number of Vaccinex Shares calculated pursuant to the Exchange Ratio. As of the date hereof, the
Investors hold an aggregate of 12,025,873 Units which are exchangeable hereunder for an aggregate of 12,025,873 Vaccinex Shares. 

  

	    	“Exchange Notice” means a notice, in substantially the form of Schedule A attached hereto, provided by or on behalf of an Investor to exercise such Investor’s Exchange Right.


  

	    	“Exchange Ratio” means 1 Vaccinex Share for every 1 Unit transferred pursuant to an Exchange (subject to appropriate adjustment in the event of any splits, dividends, combinations, subdivisions,
recapitalizations or the like, affecting the Units or Vaccinex Shares, in each case, following the date hereof, provided, however, that no such adjustment shall be made to effect any such event affecting the Vaccinex Shares to the extent that a
corresponding adjustment is made to all issued and outstanding Units prior to such Exchange under the terms of the LPA). 

  

	    	“Exchange Right” means the right of the Investors, FCMI and Vaccinex hereunder to initiate an Exchange. 

  

	    	“LPA” means the Agreement of Limited Partnership of LP, dated as of the date hereof, between Vaccinex and the Investors. 


 

	    	“Vaccinex Shares” means shares of authorized common stock, par value $0.0001 per share, of Vaccinex. 


  
 - 2 - 









	2.	In the event of a request of an Investor made to Vaccinex to exercise such Investor’s Exchange Right in respect of all but not less than all of that Investor’s Units (“Exchange Units”):


  

	 	(a)	Such Investor will transfer to Vaccinex the Exchange Units, or such transfer may be effected by Vaccinex, pursuant to the power of attorney granted by such Investor to Vaccinex as general partner of LP under the limited
partnership agreement of LP; 

  

	 	(b)	Vaccinex will issue to such Investor the number of Vaccinex Shares as determined by the Exchange Ratio in exchange for such Exchange Units. 


 

	    	The right of Investors to exercise an Exchange Right is expressly limited to those Units held by the Investors as of the date hereof (subject to appropriate adjustment in the event of any splits, dividends,
combinations, subdivisions, recapitalizations or the like, affecting the Units following the date hereof), which Units are set forth on Schedule B to the LPA as of the date hereof. 


 

	3.	Without limiting Section 2, in the event of a request of FCMI made to Vaccinex to exercise FCMI’s Exchange Right in respect of all but not less than all of FCMI’s Units: 


 

	 	(a)	Each Investor, including FCMI, will transfer to Vaccinex all but not less than all of that Investor’s Units, or such transfer may be effected by Vaccinex, pursuant to the power of attorney granted by such Investor
to Vaccinex as general partner of LP under the limited partnership agreement of LP; 

  

	 	(b)	Vaccinex will issue to each Investor, including FCMI, the number of Vaccinex Shares as determined by the Exchange Ratio in exchange for such Investor’s Units. 


 

	4.	Vaccinex may exercise the Exchange Right at its option, at any time, so as to result in the transfer of all but not less than all of the then-outstanding Units to Vaccinex in any of the following circumstances:


  

	 	(a)	upon or in connection with the completion of such Exchange, Vaccinex distributes an amount of cash to the Investors, in the case of FCMI, equal to 15% and, in the case of all other Investors, equal to 23%, in each case,
of the fair market value of the Vaccinex Shares delivered pursuant to such Exchange, as such fair market value is reasonably determined in good faith by the Board of Directors of Vaccinex (without limitation, such cash may be made available as a
cash distribution or through the purchase or repurchase of Vaccinex Shares or Units held by or issuable to the Investors); 

  

	 	(b)	Vaccinex has entered into (including by entering into definitive documents related thereto) a transaction such as a sale, merger or consolidation such that Vaccinex Shares are or will be sold or, exchanged for cash
and/or marketable securities; 

  

	 	(c)	At any time on or after the fifth anniversary of the date hereof; and 

  

	 	(d)	Vaccinex or LP has entered into (including by entering into definitive documents related thereto) a licensing, partnering or similar transaction, including a product sale or option to enter into the foregoing, with
respect to one or more of the products and indications licensed to LP by Vaccinex, and all amounts then due and owing to LP in connection with such transaction have been paid to LP; provided, that Vaccinex will use its commercially reasonable
efforts to structure the transaction, or enter into such related transactions, such that the Investors are either able to defer tax liabilities, to the extent permitted by law, or to monetize a portion of their Units or Vaccinex Shares so as to
defray any taxes arising as a result of the transaction, in each case, in accordance with applicable law. 


  
 - 3 - 









	    	For the avoidance of doubt, (i) following the consummation of an Exchange in accordance with this Agreement with respect to all Units, other than as a holder of Vaccinex Shares, if applicable, neither LP nor the
Investors shall have a right to receive proceeds of such transaction paid to Vaccinex or LP following the consummation of such Exchange, (ii) the Parties agree and acknowledge that nothing contained in this Agreement shall require Vaccinex or
LP to obtain the consent of any Party hereto in order to enter into or consummate any such transaction. 

  

	5.	In the event either an Investor, FCMI or Vaccinex exercise their Exchange Right hereunder, each Investor, FCMI and Vaccinex shall take all steps necessary to effect the applicable Exchange on the terms and conditions
contained herein, including by taking any action reasonably requested by Vaccinex with respect to the transfer of Units. 

  

	6.	Vaccinex Shares issued in connection with an Exchange shall be issued in accordance with the registration instructions set forth in the Exchange Notice, in the absence of which they shall be issued in the name of the
applicable Investor. 

  

	7.	Notwithstanding anything herein to the contrary, if applicable, no fractional Vaccinex Shares shall be issuable upon exercise of the Exchange Right or in connection with an Exchange. If applicable, the number of
Vaccinex Shares to be issued shall be rounded down to the nearest whole number of Vaccinex Shares. 

  

	8.	Prior to the consummation of an applicable Exchange in accordance with this Agreement, no Investor shall have any rights of a holder of Vaccinex Shares, or otherwise as a stockholder of Vaccinex, including, without
limitation, the right to vote on any matter presented to the stockholders of Vaccinex or receive any dividends or distributions on Vaccinex Shares or other shares of Vaccinex stock. Following the consummation of an applicable Exchange in accordance
with this Agreement, the Investors shall not have any rights as a holder of Units, including, without limitation, with respect to the management of LP, any distribution made to the holders of Units or any other interest in LP. 


 

	9.	Vaccinex shall reserve and keep available during the term of this Agreement, out of its authorized and unissued shares of common stock, that number of Vaccinex Shares that will from time to time be sufficient to permit
the exercise in full of the Exchange Right. If in connection with the exercise of an Exchange Right, Vaccinex does not have sufficient authorized and unissued Vaccinex Shares to permit the exercise in full of the Exchange Right, Vaccinex will
promptly take such actions as are reasonably necessary to authorize additional Vaccinex Shares to permit the exercise in full of the Exchange Right, subject to applicable laws and the rights of Vaccinex stockholders. 


 

	10.	The Parties hereby represent and warrant to each other as follows: 

  

	 	(a)	Such Party has the full corporate or limited partnership power and authority, as applicable, to execute and deliver this Agreement and to carry out the transactions contemplated hereby; 


 

	 	(b)	The execution and delivery of, and performance by such Party under, this Agreement and the consummation of the transactions contemplated hereby have been duly authorized by all necessary corporate or limited partnership
action, as applicable, on the part of such Party and LP; 


  
 - 4 - 









	 	(c)	Neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated hereby will (i) violate any provision of the organizational documents of such Party, (ii) violate any
provision of applicable law binding on such Party, or (iii) conflict with, result in a breach of, or constitute a default (or an event which, with notice or lapse of time, or both, would constitute a default) under any material contract binding
on such Party; 

  

	 	(d)	Schedule A to the LPA sets forth the true, correct and complete capitalization of LP, including all issued and outstanding Units and the holders thereof, and there are no holders of equity interests in or other
securities of LP except for the Investors (all of whom are set forth on such Schedule A) and the general partnership interest and limited partnership interest of Vaccinex; and 


 

	 	(e)	Except for the Units set forth on Schedule A to the LPA, there are no outstanding units or other partnership interests in LP, or options, warrants, rights (including conversion or preemptive rights and rights of first
refusal or similar rights) or agreements, orally or in writing, to purchase or acquire from LP any units or partnership interests, or any securities convertible into or exchangeable for units or partnership interests of LP. 


 

	11.	Vaccinex and LP hereby represent and warrant to VX GP and VX LP as follows: 

  

	 	(a)	Each of Vaccinex and LP have the full corporate or limited liability company power and authority, as applicable, to execute and deliver this Agreement and to carry out the transactions contemplated hereby;


  

	 	(b)	The execution and delivery of, and performance by Vaccinex and LP under, this Agreement and the consummation of the transactions contemplated hereby have been duly authorized by all necessary corporate or limited
liability company action, as applicable, on the part of Vaccinex and LP, and no other corporate or limited liability company proceedings, as applicable, are necessary to authorize this Agreement and the transactions contemplated hereby;


  

	 	(c)	Neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated hereby will (i) violate any provision of the organizational documents of Vaccinex or LP, or
(ii) violate any provision of applicable law binding on such Party; and 

  

	 	(d)	All Vaccinex Shares which may be issued upon an Exchange hereunder shall, upon issuance in accordance with this Agreement, be duly authorized, validly issued, fully paid and nonassessable, and free of any liens and
encumbrances except as may be provided herein, restrictions under applicable federal and state securities laws, the certificate of incorporation of Vaccinex, as then in effect, or the Stockholders Agreements (as defined below) if then in effect, and
for such liens and encumbrances as may be created by an Investor. 

  

	12.	Each Party acknowledges that the Omnibus Amendment has been terminated in connection with the Consolidation. 


  
 - 5 - 









	13.	Vaccinex may not unreasonably withhold its consent from any proposed transfer of Units to any person or entity which is not an Investor as of the date hereof (as reflected on Schedule A to the LPA as of the date
hereof), and any holder of Units may, without the prior written consent of Vaccinex, transfer Units for bona fide estate planning purposes, either during or after such holder’s lifetime or upon death by will or intestacy, to his or her spouse,
child (natural or adopted), or any other direct lineal descendant of such holder (or of his or her spouse) (all of the foregoing collectively referred to as “Family Members”), or any custodian or trustee of any trust, partnership or
limited liability company for the benefit of, or the ownership interests of which are owned wholly by, such holder or any such family members; provided, that (i) such holder shall deliver prior written notice to Vaccinex of such transfer,
(ii) such Units and such transferee(s) shall remain subject to the terms of this Agreement; and (iii) such transfer shall be permitted by applicable law. 


 

	14.	The obligations of Vaccinex to issue Vaccinex Shares and the rights of any holder of Units to receive Vaccinex Shares hereunder in connection with an Exchange are expressly subject to the execution and delivery by any
recipient of Vaccinex Shares (including Investors, as applicable) of joinders or counter-part signature pages to all stockholders agreements binding on holders of Vaccinex Shares and such other documents or instruments as may be reasonably requested
by Vaccinex, which may include transfer instruments with respect to the Units, transfer restrictions applicable to other holders of Vaccinex Shares, representations and warranties of such recipient regarding their ownership of the Units and/or the
Vaccinex Shares or as may be necessary or advisable under United States federal and state securities laws (the “Stockholders Agreements”). 

  

	15.	The undersigned Parties agree that, notwithstanding Section 19(b) of the Prior Agreement, this Agreement shall amend, supersede and replace the Prior Agreement in all respects and this Agreement represents the
entire understanding between the Parties with respect to the subject matter contained herein and supersedes all prior understandings and agreements, whether oral or written, including the Prior Agreement, among the Parties with respect to the
subject matter contained herein. 

  

	16.	This Agreement shall be effective as of the date first written above upon the execution and delivery hereof by each Party hereto. 

  

	17.	This Agreement may be amended by mutual written agreement of Vaccinex and FCMI. 

  

	18.	This Agreement may be terminated by mutual written agreement of Vaccinex and FCMI, and shall automatically terminate upon (a) the consummation of the Exchange with respect to all Units or (b) upon FCMI’s
prior written consent (which consent shall not be unreasonably withheld, conditioned or delayed), a merger or consolidation of LP with or into Vaccinex or any of its direct or indirect subsidiaries or controlled affiliates. 


 

	19.	Any notice, consent, waiver or other communication given under this Agreement must be in writing and may be given by delivering it or sending it by confirmed email addressed: 


 

	 	(a)	to Vaccinex: 

  

	 	Attention:	Maurice Zauderer 


	 	Email:	mzauderer@vaccinex.com 

  

	 	with	a copy (which shall not constitute notice) to: 

  

	 	Attention:	Asher M. Rubin 


	 	Email:	asher.rubin@hoganlovells.com 


  
 - 6 - 









	 	(b)	to LP: 

  

	 	Attention:	Maurice Zauderer 


	 	Email:	mzauderer@vaccinex.com 

  

	 	with	a copy (which shall not constitute notice) to: 

  

	 	Attention:	Asher M. Rubin 


	 	Email:	asher.rubin@hoganlovells.com 

  

	 	(c)	to FCMI or FCMI Parent: 

  

	 	Attention:	Dan Scheiner 

  

	 	with	a copy (which shall not constitute notice) to: 

  

	 	Attention:	Ronald Rutman 

  

	 	    	Any such communication is deemed to have been delivered on the date of confirmed transmission, unless that day is not a business day in Canada or in the United States or if such confirmed transmission is not received
during normal business hours of the recipient, in which event it will be deemed delivered on the next following business day. Any Party may change its email address for service by notice given in accordance with the foregoing and any subsequent
notice must be sent to such Party at its changed email address. 

  

	20.	None of the Parties shall sell, transfer or assign (including by operation of law) its interest in this Agreement without (a) providing reasonable prior written notice to the other Parties, and (b) subject to
Section 13, obtaining the prior written consent of Vaccinex. Any transfer or assignment not permitted under this section shall be null and void and of no effect whatsoever. 


 

	21.	The provisions hereof shall inure to the benefit of the Parties and their respective successors and permitted assigns. 

  

	22.	Nothing in this Agreement, express or implied, is intended to confer upon any person other than the Parties hereto or their respective successors and permitted assigns and the Investors any rights, remedies,
obligations, or liabilities under or by reason of this Agreement. 

  

	23.	Without limiting anything else contained herein, the Parties shall do or cause to be done all such reasonable acts and things as may be necessary, proper, or advisable, consistent with all applicable laws, to consummate
and make effective the transactions contemplated hereby on the terms and subject to the conditions contained herein. Without limiting the foregoing, each Party shall use its commercially reasonable efforts, and the other Parties shall cooperate with
such efforts, to (a) execute and deliver, or cause to be executed and delivered, such further documents and instruments, including tax certifications and documents, in each case as may be necessary or proper in the reasonable judgment of
Vaccinex, to carry out the provisions and purposes of this Agreement and to comply with applicable legal requirements and (b) obtain any consents, approvals or authorization, or effect the notification of or filing with, each person, whether
private or governmental, whose consent or approval is required in order to permit the consummation of the transactions contemplated hereby on the terms and subject to the conditions contained herein. 


  
 - 7 - 









	24.	The construction and performance of this Agreement shall be governed by the laws of the State of Delaware. 

  

	25.	This Agreement may be executed in one or more counterparts, each of which will be deemed an original and all of which together will constitute one and the same instrument. This Agreement may be executed through delivery
of duly executed signature pages by facsimile or electronic mail. 

 [signature pages follow] 

  
 - 8 - 








 IN WITNESS WHEREOF the Parties have executed this Amended and Restated Exchange Agreement
as of the date first above written. 
  

							
		 		 	 LP
  

By: Vaccinex, Inc., its general partner

				
		 		 	By:	 	/s/ Maurice Zauderer
		 		 		 	Name: Maurice Zauderer
		 		 		 	Title: President and Chief Executive Officer


  
 - 9 - 








 IN WITNESS WHEREOF the Parties have executed this Amended and Restated Exchange Agreement
as of the date first above written. 
  

							
		 		 	VACCINEX, INC.
				
		 		 	By:	 	/s/ Maurice Zauderer
		 		 		 	Name: Maurice Zauderer
		 		 		 	Title: President and Chief Executive Officer


  
 - 10 - 








 IN WITNESS WHEREOF the Parties have executed this Amended and Restated Exchange Agreement
as of the date first above written. 
  

							
		 		 	VX PARTNERS INC.
				
		 		 	By:	 	/s/ Richard Sutin
		 		 		 	Name: Richard Sutin
		 		 		 	Title: Director

  

							
		 		 	VX2 GENERAL PARTNER INC.
				
		 		 	By:	 	/s/ Richard Sutin
		 		 		 	Name: Richard Sutin
		 		 		 	Title: Director


  
 - 11 - 








 IN WITNESS WHEREOF the Parties have executed this Amended and Restated Exchange Agreement
as of the date first above written. 
  

							
		 		 	FCMI FINANCIAL CORPORATION
				
		 		 	By:	 	/s/ Dan Scheiner
		 		 		 	Name: Dan Scheiner
		 		 		 	Title: V.P.

  

							
		 		 	FMCI PARENT CO.
				
		 		 	By:	 	/s/ Dan Scheiner
		 		 		 	Name: Dan Scheiner
		 		 		 	Title: V.P.


  
 - 12 - 








 SCHEDULE A 

EXCHANGE NOTICE 
 See attached. 

  
 - 13 - 








 EXCHANGE NOTICE 

Vaccinex, Inc. 
 1895 Mt. Hope Avenue 

Rochester, NY 14620 
  

	1.	The undersigned hereby irrevocably elects to exercise its Exchange Right in respect of all but not less than all of its Units. 

  

	2.	Please issue a certificate or certificates representing the Vaccinex Shares issuable upon the exchange of such Units in the name of the undersigned or in such other name as is specified below: 


 
  
  

 
  

 
 (please print name and address above) 

 

	3.	The undersigned represents it is acquiring the Vaccinex Shares solely for its own account and not as a nominee for any other party and not with a view toward the resale or distribution thereof except in compliance with
applicable securities laws. 

  

	4.	Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Amended and Restated Exchange Agreement, dated October 24, 2014, among Vaccinex, Inc., VX Partners Inc., VX2
General Partners Inc., Vaccinex Products, LP, FCMI Financial Corporation, and FCMI Parent Co. 

  

 
  

[INVESTOR’S NAME] 
  

 
  

Date: 

  
 - 14 -